RECORD // Company

Aytu Biopharma, Inc

Formerly: AYTU BIOSCIENCE, INC; Rosewind CORP

Built 2026-11-22T05:01:29Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Records under a former name (4)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (8)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • AYTU BIOPHARMA, INC. · Ct business · same registered legal name as 'AYTU BIOPHARMA, INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Aytu BioPharma, Inc. · Ctgov · same registered legal name as 'AYTU BIOPHARMA, INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AYTU BIOPHARMA, INC. · East licences · same registered legal name as 'AYTU BIOPHARMA, INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AYTU BIOPHARMA, INC. · East licences · same registered legal name as 'AYTU BIOPHARMA, INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AYTU BIOPHARMA, INC. · East licences · same registered legal name as 'AYTU BIOPHARMA, INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AYTU BIOPHARMA, INC. (FORMERLY KNOWN AS AYTU BIOSCIENCE, INC.) (lobbying via DORSEY & WHITNEY LLP) · LDA lobbying · same registered legal name as 'AYTU BIOPHARMA, INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AYTU BIOPHARMA, INC. · Ny corps · same registered legal name as 'AYTU BIOPHARMA, INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AYTU BIOPHARMA, INC · USAspending · same registered legal name as 'AYTU BIOPHARMA, INC' Possible match based on name, not a shared identifier. Compare the records. Compare

6 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001437749-26-037188

ItemValuePeriodFormFiledAccessionReport
Revenue$14,842,0003 months ended 2026-09-3010-Q2026-11-160001437749-26-0371882026-11-22 05:01 UTCReport an error
Net income (loss)$-3,881,0003 months ended 2026-09-3010-Q2026-11-160001437749-26-0371882026-11-22 05:01 UTCReport an error
Interest expense$408,0003 months ended 2026-09-3010-Q2026-11-160001437749-26-0371882026-11-22 05:01 UTCReport an error
Cash and cash equivalents$25,494,000at 2026-09-3010-Q2026-11-160001437749-26-0371882026-11-22 05:01 UTCReport an error
Debt due in the next 12 months$1,857,000at 2026-09-3010-Q2026-11-160001437749-26-0371882026-11-22 05:01 UTCReport an error
Debt due in year 2$7,429,000at 2026-09-3010-Q2026-11-160001437749-26-0371882026-11-22 05:01 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001385818
Ticker
AYTU
EIN
470883144
CUSIP
054754858
Record ID
sx:sec:0001385818

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

35 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-20SEC EDGAR company profile2026-11-22 05:01 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-20SEC EDGAR company profile2026-11-22 05:01 UTCReport an error
State of incorporationDE2026-11-20SEC EDGAR company profile2026-11-22 05:01 UTCReport an error
Fiscal year end (MMDD)06302026-11-20SEC EDGAR company profile2026-11-22 05:01 UTCReport an error
Business address7900 E. UNION AVENUE, SUITE 920, DENVER, CO, 802372026-11-20SEC EDGAR company profile2026-11-22 05:01 UTCReport an error
ExchangesNasdaq2026-11-20SEC EDGAR company profile2026-11-22 05:01 UTCReport an error
Revenue (fiscal year ended 2026-06-30)$57,570,0002026-06-3010-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-22 05:01 UTCReport an error
Net income (loss) (fiscal year ended 2026-06-30)$-14,252,0002026-06-3010-K, XBRL NetIncomeLoss2026-11-22 05:01 UTCReport an error
Total assets (at 2026-06-30)$105,007,0002026-06-3010-K, XBRL Assets2026-11-22 05:01 UTCReport an error
Stockholders' equity (at 2026-06-30)$35,274,0002026-06-3010-K, XBRL StockholdersEquity2026-11-22 05:01 UTCReport an error
Cash and cash equivalents (at 2026-06-30)$26,308,0002026-06-3010-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 05:01 UTCReport an error
Operating cash flow (fiscal year ended 2026-06-30)$3,281,0002026-06-3010-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 05:01 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2026-06-30)$29,0002026-06-3010-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 05:01 UTCReport an error
Long-term debt (at 2026-06-30)$9,101,0002026-06-3010-K, XBRL LongTermDebtNoncurrent2026-11-22 05:01 UTCReport an error
Operating lease liabilities (at 2026-06-30)$1,074,0002026-06-3010-K, XBRL OperatingLeaseLiability2026-11-22 05:01 UTCReport an error
Form D total offering amount (D filed 2019-10-31)$10,000,0002019-10-31D2026-11-22 05:01 UTCReport an error
Form D total amount sold (D filed 2019-10-31)$10,000,0002019-10-31D2026-11-22 05:01 UTCReport an error
Form D industry groupPharmaceuticals2019-10-31D2026-11-22 05:01 UTCReport an error
Form D revenue rangeDecline to Disclose2019-10-31D2026-11-22 05:01 UTCReport an error
Form D date of first sale2019-10-162019-10-31D2026-11-22 05:01 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-16)On November 16, 2026, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2027 first quarter operational and financial results. Due to the pending merger with Rosemont Pharmaceuticals Holdings, Inc. (“Rosemont”), the Company will not be holding an earnings conference call to discuss its financial results. The information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall…2026-11-16SEC EDGAR 8-K 0001437749-26-037176 (text as filed, excerpt)2026-11-22 05:01 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-11-16)On November 16, 2026, Aytu BioPharma Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Rosemont Pharmaceuticals Holdings, Inc., a Delaware corporation (“Parent”), and RoseApollo Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”). The Merger Agreement provides for the acquisition of the Company by Parent in a two-step transaction, consisting of a tender offer and, subject to the terms of the Merger Agreement and conditioned upon the consummation of the Offer, a subsequent merger of Purchaser with and into the Company (the “Merger”), with the Company continuing as the surviving…2026-11-16SEC EDGAR 8-K 0001437749-26-037155 (text as filed, excerpt)2026-11-22 05:01 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-16)On November 16, 2026, the Company issued a press release announcing the execution of the Merger Agreement described above. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1. The information contained in the accompanying Exhibit 99.1 is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information contained in the press release shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether…2026-11-16SEC EDGAR 8-K 0001437749-26-037155 (text as filed, excerpt)2026-11-22 05:01 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-09-22)On September 22, 2026, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 fourth quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for September 22, 2026, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (available live and for replay), and the press release includes instructions for accessing the webcast via the Company’s website or dialing in to the call. A replay of the call will be made available after the call on the Company’s website and via…2026-09-22SEC EDGAR 8-K 0001437749-26-030900 (text as filed, excerpt)2026-11-22 05:01 UTCReport an error
Plan (pension, plan no. 002)AYTU BIOPHARMA EMPLOYEE RETIREMENT PLAN: 200 participants, assets $16,917,6512025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 05:01 UTCReport an error
Largest institutional holder #1 (13F as filed): Nantahala Capital Management, LLC$4,673,2922026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:01 UTCReport an error
Largest institutional holder #2 (13F as filed): Stonepine Capital Management, LLC$1,962,7802026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:01 UTCReport an error
Largest institutional holder #3 (13F as filed): AWM Investment Company, Inc.$1,332,0842026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:01 UTCReport an error
Largest institutional holder #4 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$561,4642026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:01 UTCReport an error
Largest institutional holder #5 (13F as filed): CROWN ADVISORS MANAGEMENT, INC.$430,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:01 UTCReport an error
Largest institutional holder #6 (13F as filed): DIADEMA PARTNERS LP$319,3742026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:01 UTCReport an error
Largest institutional holder #7 (13F as filed): TWO SIGMA INVESTMENTS, LP$226,4512026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:01 UTCReport an error
Largest institutional holder #8 (13F as filed): RENAISSANCE TECHNOLOGIES LLC$225,3692026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:01 UTCReport an error
Largest institutional holder #9 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$201,3712026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:01 UTCReport an error
Largest institutional holder #10 (13F as filed): CITADEL ADVISORS LLC$106,2402026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:01 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.